Clinical trial designs for targeted agents

被引：10

作者：

Ma, BBY

Britten, CD

Siu, LL

机构：

[1] Univ Toronto, Princess Margaret Hosp, Hlth Network, Dept Med Oncol, Toronto, ON M5G 2M9, Canada

[2] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2002年 / 16卷 / 05期

关键词：

D O I：

10.1016/S0889-8588(02)00045-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The unique properties of contemporary targeted drugs pose major challenges for the development of anticancer therapy, necessitating modification of traditional clinical trial designs. This article discusses some of the strategies employed to evaluate these agents in the phase I to 111 setting, citing examples of some recently tested targeted agents to illustrate the advantages and disadvantages of various approaches.

引用

收藏

页码：1287 / +

页数：20

相关论文

共 79 条

[1] Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 [J].

Albanell, J ;

Rojo, F ;

Baselga, J .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :56-66

[2] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[3] CLINICAL TRIAL DESIGN AVOIDING UNDUE PLACEBO TREATMENT [J].

AMERY, W ;

DONY, J .

JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 15 (10) :674-679

[4] Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques [J].

Anderson, H ;

Price, P ;

Blomley, M ;

Leach, MO ;

Workman, P .

BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1085-1093

[5]

Arbuck SG, 1996, ANN ONCOL, V7, P567

[6]

ATKINS MB, 2002, P AM CLIN ONCOL, P21

[7] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[8] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[9]

COLLIE MA, 2002, P AM CLIN ONCOL, P21

[10] PHARMACOLOGICALLY GUIDED PHASE-I CLINICAL-TRIALS BASED UPON PRECLINICAL DRUG DEVELOPMENT [J].

COLLINS, JM ;

GRIESHABER, CK ;

CHABNER, BA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (16) :1321-1326

← 1 2 3 4 5 6 7 8 →